These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38490696)

  • 1. Concordance and agreement between different activity scores in polymyalgia rheumatica.
    D'Agostino J; Souki A; Lohse A; Carvajal Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel B; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A; Devauchelle-Pensec V
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38490696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
    Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
    JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.
    Devauchelle-Pensec V; Saraux L; Berthelot JM; De Bandt M; Cornec D; Guellec D; Marhadour T; Jousse-Joulin S; Gouillou M; Saraux A
    Rheumatology (Oxford); 2018 Apr; 57(4):666-670. PubMed ID: 29346621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Allard B; Devauchelle-Pensec V; Saraux A; Nowak E; Tison A; Boukhlal S; Guellec D; Jousse-Joulin S; Cornec D; Marhadour T; Le Pennec R; Salaün PY; Querellou S
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1297-1309. PubMed ID: 38095675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.
    Saraux A; Le Henaff C; Dernis E; Carvajal-Alegria G; Tison A; Quere B; Petit H; Felten R; Jousse-Joulin S; Guellec D; Marhadour T; Kervarrec P; Cornec D; Querellou S; Nowak E; Souki A; Devauchelle-Pensec V
    Lancet Rheumatol; 2023 Dec; 5(12):e728-e735. PubMed ID: 38251563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial.
    Bolhuis TE; Marsman DE; den Broeder AA; den Broeder N; van der Maas A
    Lancet Rheumatol; 2023 Apr; 5(4):e208-e214. PubMed ID: 38251523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.
    Martinez-Taboada VM; Blanco R; Fito C; Pacheco MJ; Delgado-Rodriguez M; Rodriguez-Valverde V
    Semin Arthritis Rheum; 2001 Feb; 30(4):257-71. PubMed ID: 11182026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic difficulties in polymyalgia rheumatica cases with normal erythrocyte sedimentation rate and C-reactive protein values.
    Kara M; Alp G; Koç AM
    Medicine (Baltimore); 2023 Sep; 102(39):e35385. PubMed ID: 37773830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methods for assessment of disease activity of polymyalgia rheumatica].
    Reisch M; Dejaco C
    Z Rheumatol; 2023 Jun; 82(5):368-379. PubMed ID: 37184675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study.
    Cantini F; Salvarani C; Olivieri I; Macchioni L; Ranzi A; Niccoli L; Padula A; Boiardi L
    Semin Arthritis Rheum; 2000 Aug; 30(1):17-24. PubMed ID: 10966209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment.
    Palard-Novello X; Querellou S; Gouillou M; Saraux A; Marhadour T; Garrigues F; Abgral R; Salaün PY; Devauchelle-Pensec V
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):773-9. PubMed ID: 26753600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
    Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
    Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma fibrinogen along with patient-reported outcome measures enhances management of polymyalgia rheumatica: a prospective study.
    McCarthy EM; MacMullan PA; Al-Mudhaffer S; Madigan A; Donnelly S; McCarthy CJ; Molloy ES; Kenny D; McCarthy GM
    J Rheumatol; 2014 May; 41(5):931-7. PubMed ID: 24692520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.
    van der Geest KS; Abdulahad WH; Rutgers A; Horst G; Bijzet J; Arends S; Roffel MP; Boots AM; Brouwer E
    Rheumatology (Oxford); 2015 Aug; 54(8):1397-402. PubMed ID: 25724206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.
    Kyle V; Cawston TE; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):667-71. PubMed ID: 2782977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polymyalgia rheumatica: new developments and challenges].
    Marsman DE; den Broeder AA; Boers N; van der Maas A
    Ned Tijdschr Geneeskd; 2017; 161():D1647. PubMed ID: 29192568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica.
    van Sleen Y; Graver JC; Abdulahad WH; van der Geest KSM; Boots AMH; Sandovici M; Brouwer E
    Front Immunol; 2019; 10():1981. PubMed ID: 31507597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial.
    Ma X; Yang F; Wu J; Xu B; Jiang M; Sun Y; Sun C; Yu Y; Xu D; Xiao L; Ren C; Chen C; Ye Z; Liang J; Lin J; Chen W
    PLoS Med; 2023 Jun; 20(6):e1004249. PubMed ID: 37384596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations.
    Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Spacca C; Lodi L; Portioli I
    J Rheumatol; 1992 Jul; 19(7):1100-6. PubMed ID: 1512765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
    Bonelli M; Radner H; Kerschbaumer A; Mrak D; Durechova M; Stieger J; Husic R; Mandl P; Smolen JS; Dejaco C; Aletaha D
    Ann Rheum Dis; 2022 Jun; 81(6):838-844. PubMed ID: 35210264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.